Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Harvard Business School
Cantor Fitzgerald
AstraZeneca
Merck
Argus Health
Colorcon
Cerilliant
QuintilesIMS

Generated: October 22, 2018

DrugPatentWatch Database Preview

Oak Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for OAK PHARMS, and what generic alternatives to OAK PHARMS drugs are available?

OAK PHARMS has fifteen approved drugs.

There are seven US patents protecting OAK PHARMS drugs.

Summary for Oak Pharms
US Patents:7
Tradenames:11
Ingredients:11
NDAs:15

Drugs and US Patents for Oak Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-004 Jul 18, 2003 AN RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-002 Mar 25, 1999 AN RX Yes Yes 6,451,289 ➤ Try a Free Trial ➤ Try a Free Trial
Oak Pharms Akorn COGENTIN benztropine mesylate INJECTABLE;INJECTION 012015-001 Approved Prior to Jan 1, 1982 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Oak Pharms NEMBUTAL SODIUM pentobarbital sodium INJECTABLE;INJECTION 083246-001 Approved Prior to Jan 1, 1982 AP RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial
Oak Pharms Inc BETIMOL timolol SOLUTION/DROPS;OPHTHALMIC 020439-002 Mar 31, 1995 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Oak Pharms NEMBUTAL pentobarbital sodium SUPPOSITORY;RECTAL 083247-004 Jan 25, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Oak Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-001 Mar 25, 1999 6,083,993 ➤ Try a Free Trial
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-004 Jul 18, 2003 5,760,090 ➤ Try a Free Trial
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-003 Jan 30, 2002 5,760,090 ➤ Try a Free Trial
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-001 Mar 25, 1999 5,362,755 ➤ Try a Free Trial
Oak Pharms Inc AZASITE azithromycin SOLUTION/DROPS;OPHTHALMIC 050810-001 Apr 27, 2007 5,192,535 ➤ Try a Free Trial
Oak Pharms Inc XOPENEX levalbuterol hydrochloride SOLUTION;INHALATION 020837-004 Jul 18, 2003 5,844,002 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for OAK PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Ophthalmic Solution 1% ➤ Subscribe 2011-03-03
➤ Subscribe Ophthalmic Solution 0.0015% ➤ Subscribe 2016-02-10
➤ Subscribe Inhalation Solution 0.0025 ➤ Subscribe 2006-05-23
➤ Subscribe Ophthalmic Solution 2%/0.5% ➤ Subscribe 2005-10-11
➤ Subscribe Inhalation Solution 0.0103%, 0.021% and 0.042% ➤ Subscribe 2005-06-20
➤ Subscribe Inhalation Aerosol 0.045 mg/actuation ➤ Subscribe 2012-02-27

Supplementary Protection Certificates for Oak Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 00041 Denmark ➤ Try a Free Trial
00095 Netherlands ➤ Try a Free Trial PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C0033 France ➤ Try a Free Trial PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
09/010 Ireland ➤ Try a Free Trial PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/08/491/001-EU/1/08/491/080 20090116; FIRST REGISTRATION NO/DATE: 58935 01 58935 02 58935 03 58935 04 20081028
C/GB99/043 United Kingdom ➤ Try a Free Trial PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
C0025 Belgium ➤ Try a Free Trial PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Healthtrust
QuintilesIMS
Queensland Health
Citi
Chubb
McKinsey
Chinese Patent Office
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.